Jaguar Animal Health (JAGX) to Release Quarterly Earnings on Monday

Posted by Defense World Staff on Apr 4th, 2026

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) is anticipated to announce its Q4 2025 results after the market closes on Monday, April 6th. Analysts expect the company to announce earnings of ($4.26) per share and revenue of $4.21 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 10, 2026 at 4:00 PM ET.

Jaguar Animal Health Price Performance

NASDAQ JAGX opened at $0.40 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08. Jaguar Animal Health has a 52 week low of $0.31 and a 52 week high of $15.48. The firm has a market capitalization of $1.50 million, a price-to-earnings ratio of -0.01 and a beta of 0.27. The company has a fifty day moving average of $0.57 and a two-hundred day moving average of $1.20.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JAGX. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $60.00.

Check Out Our Latest Analysis on Jaguar Animal Health

Jaguar Animal Health Company Profile

(Get Free Report)

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.